CO-TENIDONE BP

Land: Irland

Sprache: Englisch

Quelle: HPRA (Health Products Regulatory Authority)

Kaufe es jetzt

Herunterladen Fachinformation (SPC)
13-06-2024

Wirkstoff:

ATENOLOL CHLORTALIDONE

Verfügbar ab:

Norton Waterford

Darreichungsform:

Tablets

Berechtigungsdatum:

1996-10-10

Fachinformation

                                PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Co-Tenidone Tablets BP 100/25mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains Atenolol 100mg and Chlorthalidone 25mg.
3 PHARMACEUTICAL FORM
Circular, white film coated tablets embossed 'Co-Ten 100' on
one side, plain on the reverse.
4 CLINICAL PARTICULARS 
4.1 THERAPEUTIC INDICATIONS
The management of hypertension.
4.2 POSOLOGY AND METHOD OF ADMINSTRATION
_Adults:_
One tablet daily.
Older patients with hypertension who do not respond to
low dose therapy with a single agent should
have a satisfactory 
response to a single tablet daily
of Co-Tenidone 50/12.5mg. Where hypertensive control is not achieved,
addition of a 
small dose of a third agent e.g. a vasodilator may
be appropriate. 
_Elderly:_
Dosage requirements are often lower in
this age group. Older patients with hypertension who do
not respond to low 
dose therapy with a single agent should have a satisfactory
response to a single tablet daily of Co-Tenidone 50/12.5mg.
Where hypertensive control is not achieved, addition
of a small dose of a third agent, e.g. a vasodilator may be 
appropriate.
_Children:_
There is no paediatric experience of this drug and
it is therefore not recommended for use in children.
_Renal Failure:_
In patients with severe renal impairment a reduction in daily
dosage or in frequency of administration may be 
necessary.
4.3 CONTRAINDICATIONS
1.
2
nd
 or 3
rd
 degree atrioventricular block
2.
Severe bradycardia
3.
Uncontrolled or digitalis/diuretic refractory heart failure
4.
Cardiogenic shock
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 16/03/2006_
_CRN 2021092_
_page number: 1_
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE
_Cardiac_
Special care should
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Suchen Sie nach Benachrichtigungen zu diesem Produkt

Dokumentverlauf anzeigen